Novel pipeline therapies to drive diabetic neuropathic pain market across 7MM to $3 bn in 2031:…
The growth will be driven by the potential introduction of four promising late-stage pipeline products and an increase in the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Diabetic Neuropathic Pain
Evotec receives €3 million payment for Bayer starting phase-II clinical development of DNP programme
The phase-II study is anticipated to run until the end of 2022